Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (12): 1105-1109.doi: 10.35541/cjd.20210744

• Expert Commentary • Previous Articles     Next Articles

Diagnosis and treatment of chronic urticaria: current status and future prospects

Zhao Zuotao#br# #br#   

  1. Department of Dermatology and Venereology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China

  • Received:2021-10-12 Revised:2021-11-17 Online:2021-12-15 Published:2021-12-01
  • Contact: Zhao Zuotao
  • Supported by:
    Joint Sino-German Research Project of National Natural Science Foundation of China and DFG(GZ901)

Abstract: 【Abstract】 The etiology and pathogenesis of chronic urticaria are complex. The main traditional treatment is oral antihistamines. With the progressive development in the biomedical field, targeted therapy has gradually become a new treatment option. Anti-immunoglobulin E monoclonal antibodies (omalizumab) can rapidly improve patients′ condition and enhance their quality of life during the treatment of chronic urticaria, and its clinical efficacy and safety have been gradually confirmed in clinical practice. This article summarizes and analyzes the current status of clinical diagnosis and treatment of chronic urticaria, discusses some common problems and corresponding strategies, and provides a reference for clinical management of these patients.

Key words: Urticaria, Mast cells, Immunoglobulin E, Histamine antagonists, Omalizumab